[Reduction of stuttering through bronchodilatation with beta2 sympathomimetic drug formoterol]

Cas Lek Cesk. 2009;148(9):424-8.
[Article in Czech]

Abstract

Background: About 60 millions of people on the planet suffer from stuttering. Speech fluency disorder caused by stuttering (F98.5) was known already in the ancient civilizations of Egypt, Mesopotamia and China 7000 years ago (1). Despite of this the aetiology of stuttering has remained unknown and its causal treatment has not been possible.

Methods and results: According to ICD-CD, 10th revision (2) ICD-10, stuttering belongs to "Other behavioral disorders including emotional ones with their beginning in childhood and adolescence" (F98) and it is related to Chapter V "Mental and behavioral disorders" (F00-F99). A multi-centre clinical study FORZAK-0503 (3), confirmed (4) hypothetical assumption (5) of the influence of pneumoobstruction of the tracheobronchal tree on the fluency disorder. Poetically spoken, the door opened towards causal reduction of speech disfluency accompanied often by tormentous stuttering (6).

Conclusions: Besides publishing new findings on the aetiology of stuttering, it is needed to transfer stuttering under different classification and different identification code within ICD-10 (MKN-10).

Publication types

  • Clinical Trial
  • English Abstract
  • Multicenter Study

MeSH terms

  • Adolescent
  • Adrenergic beta-Agonists / therapeutic use*
  • Adult
  • Bronchodilator Agents / therapeutic use*
  • Child
  • Ethanolamines / therapeutic use*
  • Female
  • Formoterol Fumarate
  • Humans
  • Male
  • Stuttering / drug therapy*
  • Stuttering / physiopathology
  • Young Adult

Substances

  • Adrenergic beta-Agonists
  • Bronchodilator Agents
  • Ethanolamines
  • Formoterol Fumarate